...
首页> 外文期刊>Clinical Pediatric Endocrinology >Serum Growth-Hormone-Binding Protein and Growth during Treatment of Children with Hyperthyroidism and Hypotyroidism
【24h】

Serum Growth-Hormone-Binding Protein and Growth during Treatment of Children with Hyperthyroidism and Hypotyroidism

机译:甲状腺功能亢进症和甲状腺功能减退症儿童治疗期间的血清生长激素结合蛋白及其生长

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Thyroid hormone greatly influences postnatal growth in children and secretion of growth hormone (GH). To study the relation between serum GH-binding protein (GHBP), which is expressed as tissue GH-receptor concentrations and influenced by the nutritional state, thyroid hormone and growth development, we measured serum GHBP in six children with hyperthyoidism and six children with hypothyroidism using samples taken before and during treatment. Mean treatment periods of these diseases are 13 and 10 months, respectively. Mean height velocity standard deviation (SD) score decreased from 2.51 to -0.62, but was not significantly related to the treatment, in hyperthyroidism, and significantly increased from -3.02 to 5.27 due to the treatment in hypothyroidism. There was no significant difference of GHBP levels before the treatment between hyper- and hypothyroidism (mean 9.59 vs. 8.53ng/mL). In hyperthyroidism, GHBP levels decreased significantly during the treatment. In hypothyroidism, insulin-like growth factor I (IGF-I) and IGF binding protein-3 (IGFBP-3) increased, but percent overweight decreased significantly, and GHBP levels did not significantly change during the treatment.ΔGHBP was defined as the change in GHBP during treatment to examine whether or not the change in GHBP was parallel to the change in thyroid hormone. ΔGHBP showed no correlation with Δ height velocity SD score. ΔGHBP showed a significant positive correlation with ΔT4 level and negative correlation with Δpercent overweight. However, only ΔT4 was identified as an influencing factor on ΔGHBP by stepwise multiple regression analysis.The data demonstrate that the changes in serum GHBP level were influenced by the changes in T4 levels during the treatment of abnormal thyroid function. The data also show that GHBP was unrelated to height gain associated with treatment in hyperthyroidism and hypothroidism.
机译:甲状腺激素极大地影响儿童的出生后生长和生长激素(GH)的分泌。为了研究以组织GH受体浓度表示并受营养状态,甲状腺激素和生长发育影响的血清GH结合蛋白(GHBP)的关系,我们测量了6例甲状腺功能亢进患儿和6例甲状腺功能减退患儿的血清GHBP。使用治疗之前和治疗期间采集的样品。这些疾病的平均治疗时间分别为13个月和10个月。甲状腺功能亢进症的平均身高速度标准差(SD)评分从2.51降低至-0.62,但与治疗无显着相关性,而甲状腺功能减退症的治疗则使平均身高速度标准差(SD)评分从-3.02显着提高至5.27。甲亢和甲状腺功能减退之间的GHBP水平在治疗前无显着差异(平均9.59对8.53ng / mL)。在甲亢中,GHBP水平在治疗期间显着下降。在甲状腺功能减退症中,胰岛素样生长因子I(IGF-I)和IGF结合蛋白3(IGFBP-3)增加,但超重百分比显着降低,并且在治疗期间GHBP水平没有显着变化.ΔGHBP被定义为变化在治疗期间使用GHBP进行检查,以检查GHBP的变化是否与甲状腺激素的变化平行。 ΔGHBP与Δ身高速度SD评分无相关性。 ΔGHBP与ΔT4水平呈显着正相关,与Δ%超重呈负相关。但是,通过逐步多元回归分析,只有ΔT4被确定为ΔGHBP的影响因素。数据表明,在甲状腺功能异常的治疗过程中,血清GHBP水平的变化受T4水平的变化影响。数据还表明,GHBP与甲亢和甲状腺机能亢进的治疗相关的身高增加无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号